6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71877-9 ◽

2011 ◽

Vol 47 ◽

pp. S461

Author(s):

S. Ricci ◽

P. Ruszniewski ◽

P. Tomasetti ◽

V. Jehl ◽

S. Saletan ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Octreotide Lar ◽

Multicenter Phase

Download Full-text

6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71882-2 ◽

2011 ◽

Vol 47 ◽

pp. S462-S463 ◽

Cited By ~ 1

Author(s):

M. Pavel ◽

N. Singh ◽

V. Passos ◽

K. Oberg

Keyword(s):

Neuroendocrine Tumours ◽

Somatostatin Analog ◽

Phase Iii ◽

Phase Iii Trial ◽

Octreotide Lar ◽

Multicenter Phase

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Everolimus + Octreotide LARvs.Placebo + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2): Updated Safety Results

10.1210/endo-meetings.2011.part3.or6.or25-1 ◽

2011 ◽

pp. OR25-1-OR25-1

Author(s):

David Gross ◽

Marc Peeters ◽

Valentine Jehl ◽

Stephen Saletan ◽

Lucas Sideris

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Octreotide Lar ◽

Multicenter Phase

Download Full-text

6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71872-x ◽

2011 ◽

Vol 47 ◽

pp. S459 ◽

Cited By ~ 2

Author(s):

C. Lombard-Bohas ◽

E. Van Cutsem ◽

J. Capdevila ◽

E.G.E. de Vries ◽

P. Tomassetti ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Safety Data ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Pancreatic Neuroendocrine Tumours

Download Full-text

Custodiol-N versus custodiol: A prospective randomized double blind multicenter phase III trial

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0034-1367380 ◽

2014 ◽

Vol 62 (S 01) ◽

Author(s):

G. Szabó ◽

A. Weymann ◽

B. Schmack ◽

D. Badowsky-Zyla ◽

G. Veres ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Multicenter Phase

Download Full-text

Updated Results from the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-00145 ◽

2011 ◽

Vol 106 ◽

pp. S59 ◽

Cited By ~ 1

Author(s):

Edward Wolin ◽

Rodney Pommier ◽

Jeremie Lincy ◽

Robert Winkler ◽

James Yao

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Pancreatic Neuroendocrine Tumors ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial

Rheumatology ◽

10.1093/rheumatology/keu132 ◽

2014 ◽

Vol 53 (9) ◽

pp. 1654-1663 ◽

Cited By ~ 36

Author(s):

C. Bao ◽

F. Huang ◽

M. A. Khan ◽

K. Fei ◽

Z. Wu ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Phase Iii ◽

Chinese Patients ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

Endocrine Abstracts ◽

10.1530/endoabs.32.p847 ◽

2013 ◽

Cited By ~ 3

Author(s):

Pamela Freda ◽

Maria Fleseriu ◽

der Lely Aart Jan van ◽

Annamaria Colao ◽

Michael Sheppard ◽

...

Keyword(s):

Phase Iii ◽

Biochemical Control ◽

Double Blind ◽

Octreotide Lar ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

Endocrine Abstracts ◽

10.1530/endoabs.32.p845 ◽

2013 ◽

Author(s):

Michael Sheppard ◽

Marcello Bronstein ◽

Pamela Freda ◽

Omar Serri ◽

Marinis Laura De ◽

...

Keyword(s):

Phase Iii ◽

Extension Phase ◽

Double Blind ◽

Octreotide Lar ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

1156O Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1369 ◽

2020 ◽

Vol 31 ◽

pp. S770

Author(s):

J. Xu ◽

L. Shen ◽

C. Bai ◽

J. Li ◽

Z. Zhou ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Pancreatic Neuroendocrine Tumours

Download Full-text

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4507 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4507-4507 ◽

Cited By ~ 23

Author(s):

W. Vervenne ◽

J. Bennouna ◽

Y. Humblet ◽

S. Gill ◽

M. J. Moore ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text